FDA
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired H
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Announces The New England Journal of Medicine Publication of Phase 3 TRANSCEND Trial Results in Acquired Hypothalamic Obesity
-
-
-
-
-
-
-
Rhythm Pharmaceuticals schedules call on Prader-Willi syndrome trial data
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
-
-
-
-
-
-
-
Rhythm Pharmaceuticals appoints Kim Popovits to board
-
-
-
-
-
-
-
Rhythm Pharmaceuticals Announces FDA Approval of IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
-
-
-
-
-
-
-
Rhythm Pharmaceuticals (RYTM) PT Raised to $143 at Guggenheim
-
330,677 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

